Epitope binning, via techniques like SPR and BLI, is commonly used due to its speed, cost, and throughput - but binning gives no information about epitope location, residue involvement in binding, and target structure. But what if you could pursue a binning assay that gave you bins AND the location of those bins on the epitope - without compromising on the benefits binning provides? Read on to learn about how we enable just that - our high-resolution epitope profiling service provides structural bins so you can pursue structurally-informed antibody development at the earliest stages of discovery. That means no more surprises about epitope location, identity, or diversity (or lack thereof!).
Epitope binning is typically used in the early stages of drug development to categorize antibodies by their binding sites. Conventional approaches, like surface plasmon resonance or biolayer inferometry, have a major limitation: they give no information about the actual location or structure of the epitope on the antigen. Additionally, conventional epitope binning relies on a limited set of experimental conditions and may not capture the full range of antibody binding specificities. And without structural information, the interpretation of epitope binning results can be complex and subjective, resulting in inconclusive and failed experiments.
Submit the form below and we'll send the brief right to your inbox.
Our approach to high-resolution epitope profiling - antigen structure, epitope bins, and mapped bin locations
How we compare with and improve-upon conventional epitope binning via SPR or BLI
Ways to leverage the data for efficiency gains in antibody engineering, affinity maturation, and later development phases
An understanding of how structure can influence and enhance antibody development at the earliest stages